These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15215494)

  • 1. HIV drug resistance.
    Calmy A; Pascual F; Ford N
    N Engl J Med; 2004 Jun; 350(26):2720-1. PubMed ID: 15215494
    [No Abstract]   [Full Text] [Related]  

  • 2. Prioritizing antiretrovirals for second-line therapy in resource-limited countries.
    Naidoo K
    AIDS Clin Care; 2008 May; 20(5):43. PubMed ID: 19230296
    [No Abstract]   [Full Text] [Related]  

  • 3. When to switch for antiretroviral treatment failure in resource-limited settings?
    Vekemans M; John L; Colebunders R
    AIDS; 2007 May; 21(9):1205-6. PubMed ID: 17502731
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
    Gallant JE
    Clin Infect Dis; 2007 Feb; 44(3):453-5. PubMed ID: 17205458
    [No Abstract]   [Full Text] [Related]  

  • 5. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries.
    Kuritzkes D; Lange J; Zewdie D
    Nat Med; 2003 Nov; 9(11):1343-4. PubMed ID: 14595419
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of antiretroviral failure and resistance in developing countries.
    Hawkins C; Murphy RL
    Curr Opin HIV AIDS; 2009 Nov; 4(6):538-44. PubMed ID: 20048723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance and other factors involved in therapy failure.
    Mallol S
    Antivir Ther; 2001; 6 Suppl 2():21-7. PubMed ID: 11678475
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina.
    Dilernia DA; Lourtau L; Gomez AM; Ebenrstejin J; Toibaro JJ; Bautista CT; Marone R; Carobene M; Pampuro S; Gomez-Carrillo M; Losso MH; Salomón H
    AIDS; 2007 Jun; 21(10):1355-60. PubMed ID: 17545713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV transmission and primary drug resistance.
    Turner D; Wainberg MA
    AIDS Rev; 2006; 8(1):17-23. PubMed ID: 16736948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.
    Hastings IM; Lalloo DG; Khoo SH
    AIDS; 2007 Jan; 21(2):258-9; author reply 259-60. PubMed ID: 17197825
    [No Abstract]   [Full Text] [Related]  

  • 13. New antiretroviral agents and the complexity of treatment practices.
    Smith D
    J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on antiretroviral therapy.
    Riordan A; Bugembe T
    Arch Dis Child; 2009 Jan; 94(1):70-4. PubMed ID: 18838416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
    Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
    HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of antiretroviral therapy in children in low- and middle-income countries.
    Sohn AH; Nuttall JJ; Zhang F
    Curr Opin HIV AIDS; 2010 Jan; 5(1):54-60. PubMed ID: 20046148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
    Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
    HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.